To evaluate whether PDI could serve as a potential therapeutic target in FLNC‐related DCM, we conducted a study in FlnciKO mice utilising a pan‐PDI inhibitor (E64FC26). This evidence concerns the gene P4HB and familial dilated cardiomyopathy.